Monoclonal Antibody to Phospholipase A2 Group VII (LpPLA2) Homo sapiens (Human) Monoclonal antibody

PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated

Add to Cart Distributors
Overview
Properties
  • SourceMonoclonal antibody preparation, Host Mouse
  • Ig Isotype IgG2b Kappa, Clone Number D6
  • PurificationProtein A + Protein G affinity chromatography
  • LabelNone
  • Immunogen RPA867Hu01-Recombinant Phospholipase A2 Group VII (LpPLA2)
  • Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
  • TraitsLiquid, Concentration 1mg/ml
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Monoclonal Antibody to Phospholipase A2 Group VII (LpPLA2) Packages (Simulation)
  • Monoclonal Antibody to Phospholipase A2 Group VII (LpPLA2) Packages (Simulation)
  • MAA867Hu22.jpg Figure. Western Blot; Sample: Recombinant LpPLA2, Human.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a mouse monoclonal antibody raised against LpPLA2. It has been selected for its ability to recognize LpPLA2 in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.01-2µg/mL;1:500-2000;
Immunohistochemistry: 5-20µg/mL;1:50-200;
Immunocytochemistry: 5-20µg/mL;1:50-200;
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal womenScienceDirect: S0765159710000262
  • Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver DiseaseWiley: source
  • Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over studyPubMed: 22240497
  • Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex VivoPubMed: PMC3759413
  • Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model RatsSource
  • Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.Pubmed: 23958269
  • Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes MellitusHindawi: 278063
  • The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with DyslipidemiaScirp:Source
  • In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human bloodSpringer:Source
  • Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.Pubmed:24397392
  • Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes MellitusPubmed:24818163
  • Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetesPubmed:25034387
  • Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated PatientsPubMed: 26374297
  • VEbscohost
  • Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndromepmc:PMC4803547
  • Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgeryPubmed:25773594
  • Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly …articles:10.1186
  • SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.jrnl:1841098
  • Biomarker for diagnosis of moyamoya disease:
  • Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventionsPubmed: 32859455
  • Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?

Recommend products